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Abstract
Background: Previous studies showed Scutellaria barbata D. Don extract (SBE) is a potent inhibitor in hepatoma
and could improve immune function of hepatoma H22-bearing mice. However, the immunomodulatory function of
SBE on the tumor growth of hepatoma remains unclear. This study aimed to investigate the anti-tumor effects of
SBE on hepatoma H22-bearing mice and explore the underlying immunomodulatory function.
Methods: The hepatoma H22-bearing mice were treated by SBE for 30 days. The effect of SBE on the proliferation
of HepG2 cells in vitro, the growth of transplanted tumor, the cytotoxicity of natural killer (NK) cells in spleen, the
amount of CD4+CD25+Foxp3+ Treg cells and Th17 cells in tumor tissue, and the levels of IL-10, TGF-β, IL-17A, IL-2,
and IFN-γ in serum of the hepatoma H22-bearing mice was observered. IL-17A was injected to the SBE treated
mice from day 9 post H22 inoculation to examine its effect on tumor growth.
Results: SBE treatment inhibited the proliferation of HepG2 cells in vitro with a dose-dependent manner and
significantly suppressed the tumor growth of hepatoma H22-bearing mice. Meanwhile, it increased NK cells’
cytotoxicity in spleen, down-regulated the amount of CD4+CD25+Foxp3+ Treg cells and Th17 cells in tumor tissue,
and decreased IL-10, TGF-β, and IL-17A levels (P < 0.01) whereas increased IL-2 and IFN-γ levels (P < 0.01) in the
serum of hepatoma H22-bearing mice. Moreover, administration of recombinant mouse IL-17A reversed the
anti-tumor effects of SBE.
Conclusion: SBE could inhibit the proliferation of HepG2 cells in vitro. Meanwhile, SBE also could inhibit the
growth of H22 implanted tumor in hepatoma H22-bearing mice, and this function might be associated with
immunomodulatory activity through down-regulating of Treg cells and manipulating Th1/Th17 immune response.
Keywords: Scutellaria barbata D. Don extract (SBE), Hepatoma, Immunomodulatory, H22, IL-17A, Treg cells, Th1/
Th17
* Correspondence: xjunion@126.com
2Cancer Center, Union Hospital, Tongji Medical College, Huazhong University
of Science and Technology, 1277 Jiefang Road, Wuhan 430022, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kan et al. BMC Complementary and Alternative Medicine  (2017) 17:41 
DOI 10.1186/s12906-016-1551-9
Background
Hepatocellular carcinoma (HCC) is one of the most
common human cancer that shows relatively poor prog-
nosis and rapid progression [1, 2]. The selection of HCC
treatment depends on the tumor biological behavior,
heterogeneity and liver function [3]. Faced with palliative
care, Chemotherapy is one of the main methods. How-
ever, it may cause severe side-effects and often lead to
multidrug resistance [4]. Therefore, many cancer pa-
tients tried to use Chinese herbal therapies, and several
herbs have been found to have antitumor activity and
become the main sources of anti-cancer drugs [5].
xScutellaria barbata D. Don (SB), is a perennial herb
which is natively distributed in northeast Asia. This herb
was known in traditional Chinese medicine as Ban-Zhi-
Lian and has been used as an anti-inflammatory and
anti-tumor agent [6, 7]. It was reported that flavonoids and
scutebarbatines are the main components of SB [8–10].
Scutellaria barbata D. Don extract (SBE) has been shown
to have inhibitory effects on numerous human cancers, in-
cluding hepatoma, lung cancer, colon cancer, skin cancer
[11–14]. The results of previous study showed that SBE
could inhibit the growth of hepatoma H22 cells in vitro
and in vivo, and improve immune function of the H22
tumor bearing mice [15]. However, the immunomodula-
tory function of SBE on the tumor growth of HCC remains
unclear and needs to be further investigated.
Previous studies have shown that tumor cells can re-
cruit regulatory cells (Treg) to inhibit antitumor immun-
ity in the tumor microenvironment, thus limiting the
efficiency of cancer immunotherapy [16, 17]. The role of
IL-17 and the IL-17 producing Th17 cells in cancer has re-
cently become the focus of extensive investigation [18, 19].
The proportion of Th17 cells was significantly higher in
HCC [20]. In the present study, we sought to examine the
effects of SBE on innate immunological cells, regulatory T
cells and Th17 cells in hepatoma H22-bearing mice. Our
data indicated that SBE could inhibit tumor growth of
hepatoma H22-bearing mice through modulating the im-
mune function. Our findings further provided experimen-
tal evidence for the application in the treatment of HCC.
Methods
Overall study design
Firstly, the proliferation of HepG2 cells after SBE treat-
ment was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Secondly, 40
hepatoma H22-bearing mice were randomly divided into
4 groups (n = 10) and administered for 30 days: vehicle
control group (0.9% saline solution); SBE treatment (50,
100, and 150 mg/kg/day). The growth of transplanted
tumor in the 4 groups were observered by 3D high fre-
quency color ultrasound (GE Healthcare, Milwaukee,
WI, USA) every other day. Thirty days later, the mice
were sacrificed. The concentrations of TGF-β, IL-10, IL-2,
IFN-γ and IL-17A in the serum of mice were measured by
ELISA. Meanwhile, the cytotoxicity of natural killer (NK)
cells in spleen and the amount of CD4 + CD25 + Foxp3+
Treg cells and Th17 cells in tumor tissue were observered.
Thirdly, 30 hepatoma H22-bearing mice were randomly
divided into 3 groups (n = 10) and administered for 30
days: vehicle control group (0.9% saline solution); SBE
treatment group (150 mg/kg/day); SBE (150 mg/kg/day)
combined with IL-17A (0.5 ug/mouse) treatment group.
The growth of transplanted tumor in the 3 groups were
observered by 3D high frequency color ultrasound every
other day.
Preparation of SBE
The dried rhizomes of SB were purchased from Nanjing
Haiyuan Chinese medicine decoction pieces Co., Ltd.
(Nanjing, China). And they were identified by Ruxu You,
from the department of pharmacology, Union Hospital,
Tongji Medical College, Huazhong University of Science
and Technology. The specimens were deposited in our la-
boratory under standard conditions. Briefly, the dried rhi-
zomes of SB were ground into powder. The powder (1 kg)
was extracted with double-distilled water (1000 mL) by re-
flux extraction for 1.5 h/time 2 times. Ninety-five percent
ethanol (v/v) added to the combined extract to adjust the
final concentration of ethanol to 85% (v/v). The precipi-
tated polysaccharide component was removed by the fltra-
tion device. The remaining solution was concentrated at
50 °C in a rotary evaporator under reduced pressure. Fi-
nally, the extract was redissolved in methanol for high per-
formance liquid chromatography (HPLC) analysis.
HPLC analysis
SBE was analyzed on a Pump-L 2130 HPLC system
(Hitachi, Tokyo, Japan) using an Agilent TC-C18 column
(4.6 mm× 150 mm, 5 μm). The mobile phase gradient con-
ditions consisted of methanol (A) and water (B): 0–2min,
10–10%A; 2–20min, 10–20%A; 20–40min, 20–20%A;
40–60min, 20–30%A; 60–70min, 30–60%A; 70–114min,
60–114%A. The low rate was 0.8 mL/min and the column
temperature was maintained at 25 °C. Absorbance was
measured at 264 nm.
Cell culture
Human hepatocellular carcinoma cell line (HepG2) and
mouse hepatocellular carcinoma cells line (H22) were
obtained from ATCC (American type culture collection).
Cells were cultured in dulbecco’s modified eagle media
(Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum. Human erythroleukemia cell line
K562 cells were maintained in RPMI 1640 medium sup-
plemented with 10% FBS. All cells were maintained at
37 °C in a humidified incubator gassed with 5% CO2.
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Reagents
Carboxyfluorescein succinimidyl ester, propidium iodide,
PMA, ionomycin, monensin and collagenase were pur-
chased from Sigma Company (Sigma, St. Louis, MO,
USA). Mouse TGF-β, IL-10, IL-2, IFN-γ and IL-17A
enzyme-linked immunosorbent assay (ELISA) kit was
from ebiosciences. Recombinant mouse IL-17A was from
R&D Systems. Anti-CD25-PE, anti-Foxp3-APC, anti-
CD4-FITC and anti-IL-17-PE were all from BD Company
(BD Bioscience, San Jose, CA, USA).
Hepatoma H22-bearing mice and treatment
Male BALB/c mice (18–22 g), were purchased from Center
of Medical Experimental Animals of Hubei Province
(Wuhan, China). Animal experiments were conducted ac-
cording to the Guide for the Care and Use of Laboratory
Animals of Huazhong University of Science and Technol-
ogy, as approved by the Animal Care Committee of Hubei
Province, China (Approval Number: TY20120158). BALB/
c mice were inoculated with H22 cells by subcutaneous
injection of 2 × 106 cells to the left flank. One day after im-
plantation of tumor cells, the mice were divided into 4
groups. One group was administered with saline solution
(0.9%) by intragastric administration each day (vehicle
control group), and the other 3 groups (SBE group) was
treated with SBE (50, 100, and 150 mg/kg/day) by intra-
gastric administration for continuous 30 days. One day
after implantation of tumor cells, the tumors were ob-
served under 3D ultrasound every other day, and their
volume was subsequently calculated by 3D ultrasound. To
determine the recombinant mouse IL-17A effect on the
tumor growth, IL-17A (0.5 μg per mouse) was injected
into the peritoneal cavity of SBE treated mice for 2 weeks
from day 9 after H22 inoculation.
MTT assay for HepG2 cell proliferation
The proliferation of HepG2 cells after SBE treatment was
assessed by MTT assay. Firstly, the SBE was dissolved in
50% DMSO to a stock concentration of 500 mg/ml and
stored at −20 °C, and the working concentrations of SBE
were made by diluting the stock solution in the cell culture
medium. The final concentration of DMSO in the medium
was < 0.5%. Secondly, cells were seeded into 96-well plates
at the density of 3 × 103 cells/well. After 12 h, the cells
were treated with SBE in different concentrations (0.05,
0.1, 0.2, 0.3, and 0.5 mg/mL) for 48 h, respectively. Treat-
ment with 0.5% DMSO was included as vehicle control.
Thirdly, MTT were applied to each well after treatment.
The supernatant were removed after 4 h incubation. Then,
the DMSO were added to each. The supernatants
were removed carefully and 150 μL of DMSO were
added to each well. The formazan production was ana-
lyzed at 490 nm in a plate reader (Molecular Devices,
LLC). The IC50 values were then calculated. This assay
was performed in triplicate.
NK cell cytotoxicity assay
The spleen from recipients was collected and pressed
through nylon mesh to produce a single-cell suspension.
NK cell (NK1.1+CD3−) were isolated with mouse NK cell
isolation kit ((Miltenyi Biotec, Auburn, CA). Flow cyto-
metric assay was used to assess the specific cytotoxicity of
NK cells, and K562 cell was used as a target cell. Briefly,
2 × 106 K562 (target cells) in 1 ml culture medium were
incubated with 2 μl of CFSE (400 μM) for 10 min at 37 °C
and washed with PBS three times. NK cells were mixed
with 4 × 104 labeled K562 (target cells) in a 24-well plate
with indicated effector-to-target cell (E/T) ratios (10:1,
5:1). The mixture was centrifuged to enhance cell contact
and incubated for 3 h. For the last 30 min of incubation,
10 μl of 200 μg/ml propidium iodide was added to the
cells. Samples were analyzed by FCM (BD LSR-II) imme-
diately. Each sample was prepared and analyzed in tripli-
cate. The specific killing percentage was calculated by the
following formula: [(%of target cell lysis-%of spontaneous
death)/(100-% of spontaneous death)] × 100%.
Isolation of tumor-infiltrating lymphocytes
Tumors were digested with collagenase and hyaluroni-
dase for 1 h at 37 °C. After grinding with semifrosted
slides and lysising of red blood cell, the dissociated cells
were incubated on ice for 10 min, and then spun down
at 1000 rpm for 2 min. The cell pellet was washed and
used as tumor cells. The suspension cells were underlaid
with 5 ml of lymphocyte-M solution, centrifuged at 2200
rpm for 30 min. Tumor-infiltrating lymphocytes were
harvested from the interface for FCM staining.
After incubation of TILs at 4 °C with anti-mouse CD16/
CD32mAb (2.4G2) in a staining buffer (phosphate-buffered
saline containing 2% FCS and 0.1% sodium azide) on ice
for 15 min. To detect regulatory T cells, cells were stained
with anti-Foxp3-APC after surface staining with anti-
CD25-PE and anti-CD4-FITC according to the the manu-
facturer’s protocols (BD Bioscience, San Jose, CA, USA).
To detect Th17 cells, TILs were stimulated for 4.5 h in
the presence of 50 ng/ml PMA, 1 mg/ml ionomycin, and
2 mM monensin (all from Sigma-Aldrich) at 37 °C under
5% CO2. The cells were then stained for surface markers
(anti-CD4-FITC) followed by labeling with anti-IL-17-PE
cytokine Abs. Intracellular cytokine production was then
analyzed by a LSR II flow cytometer (BD Bioscience, San
Jose, CA, USA).
Measurement of TGF-β, IL-10, IL-2, IFN-γ and IL-17A in the
serum of mice by ELISA
The mice of control and SBE treatent groups were
sacrificed, and the serum of mice were collected. The
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concentrations of TGF-β, IL-10, IL-2, IFN-γ and IL-
17A in the serum were measured by ELISA using
ELISA kits (Ebiosciences-Easy-Set-Go) according to
the manufacturer’s protocols.
Statistical analysis
Data are presented as mean ± SD. One-way analysis of
variance was used for multiple comparisons, and Student’s
t-test was used to compare two groups. P-values below
0.05 were considered as statistically significant.
Results
Identification of SBE by HPLC
The components of SBE were identified by HPLC. As
shown in Fig. 1, scutellarin, naringin, scutellarein, luteo-
lin, apigenin, wogonin, scutebarbatine A, and scutebar-
batine B were the main components of SBE and the
retention times of these peaks were ranges from 20 min
to 110 min.
SBE treatment inhibited the proliferation of HepG2 cells
The proliferation of HepG2 cells was measured by MTT
assay. After 48 h treatment of SBE, we found that it ex-
hibited a significant inhibitory effect on HepG2 cells
with a dose-dependent manner, there was significant dif-
ference among different dose of SBE (P < 0.05)., and the
IC50 was about 0.20 ± 0.21 mg/ml (Fig. 2). DMSO treat-
ment has no inhibitory effect on HepG2 cells.
SBE treatment suppressed the tumor growth of
hepatoma H22 tumor-bearing mice
Hepatoma H22-bearing mice was used to verify the anti-
cancer activities of SBE. The mice were administered with
saline solution or SBE. One day after mice implantation of
tumor cells, the tumors were observed under 3D ultra-
sound every other day, and their volume was subsequently
calculated by 3D ultrasound (Fig. 3). As shown in Fig. 4,
the volume of tumors of SBE group were significantly
smaller compared with the control group (P < 0.05).
Fig. 1 The HPLC chromatogram of SBE. a SBE; b mixed standard substances. 1: scutellarin; 2: naringin; 3: scutellarein; 4: luteolin; 5: apigenin; 6:
wogonin; 7: scutebarbatine A; 8: scutebarbatine B
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SBE treatment enhanced the NK cells’ cytotoxicity of
hepatoma H22 tumor-bearing mice
The NK cell is important for anti-tumor and virus.
Therefore, we characterized the cytotoxic effects of
spleen NK cells on K562 cells. Spleen NK (DX5+CD3−)
cells were isolated by microbeads and cytotoxicity assay
was performed by FCM at different effector-to-target (E/
T) ratios. As shown in Fig. 5, the cytotoxicity of NK cells
against K562 cells was significant enhanced by SBE
treatment (P < 0.05).
SBE treatment reduced the amount of CD4 + CD25 +
Foxp3+ regulatory T cells in tumor tissue
We investigated the effect of SBE on Treg cells infiltrat-
ing in tumor tissue. As shown in Fig. 6, the amount of
Treg cells in tumor microenvironment was significantly
decreased after SBE treatment (P < 0.05). Therefore,
these data suggested that SBE might regulate the infiltra-
tion of Treg cells in tumor microenvironment.
SBE treatment reduced the amount of CD4+IL-17+ T cells
(Th17 cell) in tumor tissue
We investigated the effect of SBE on Th17 cells infiltrat-
ing in tumor tissue. As shown in Fig. 7, the amount of
Th17 cells in tumor microenvironment was also signifi-
cantly decreased after SBE treatment (P < 0.05). There-
fore, these data suggested that SBE might regulate the
infiltration of Th17 cells in tumor microenvironment.
SBE treatment up-regulated Th1 cytokine and down-
regulated Th17 and Treg related cytokine in serum of the
hepatoma H22 tumor-bearing mice
The concentrations of TGF-β, IL-10, IL-2, IFN-γ, and IL-
17A in the serum of control and SBE treated mice were
measured by ELISA. As shown in Fig. 8, SBE treatment
significantly down-regulated Th17 and Treg related cyto-
kine, IL-17 (Fig. 8c), TGF-β (Fig. 8a), IL-10 (Fig. 8b) in the
serum of tumor bearing mice (P < 0.01). On the contrary,
Th1 related cytokine (IL-2, IFN-γ) was significantly up-
regulated in the serum of tumor bearing mice (P < 0.01).
Recombinant IL-17A administration reversed the anti-tumor
effect of SBE
One day after mice implantation of tumor cells, the tu-
mors were observed under 3D ultrasound every other
day, and their volume was subsequently calculated by
3D ultrasound (Fig. 9). As shown in Fig. 10, recombinant
IL-17A administration could reverse the anti-tumor ef-
fect of SBE, and the volume of tumors of SBE combined
with IL-17A treatment group was significantly larger
than SBE treatment group (P < 0.05), and significantly
smaller than vehicle control group (P < 0.05).
Fig. 2 Inhibitory effect of SBE on the proliferation of HepG2 cells. Cells
were treated with different concentrations of SBE. The cells viability
were determined by the MTT assay. After 48 h treatment of SBE, we
found that it exhibited a significant inhibitory effect on HepG2 cells
with a dose-dependent manner, and there was significant difference
among different dose of SBE (P < 0.05). Data are representative of three
independent experiments
Fig. 3 3D ultrasound pictures for tumor growth in SBE and saline solution treatment mice. Fifteen days after implantation of tumor cells, the
tumors of SBE and control mice were observed under 3D ultrasound, and their volume was calculated by 3D ultrasound
Kan et al. BMC Complementary and Alternative Medicine  (2017) 17:41 Page 5 of 10
Discussion
The immune system plays an important role in anti-
tumor defense. Progressive hepatocellular tumor growth is
frequently accompanied by a concomitant immunosup-
pression regardless of tumor location and etiology [21].
Tumors have evolved numerous immune escape mecha-
nisms: down-regulating of surface MHC class I molecules
to escape NK cells’ killing; the generation of cells with sup-
pression functions, including regulatory cells (Treg) and
myeloid-derived suppressor cells [22]. Therefore, based on
its pathogenesis as well as a number of correlative studies,
immunotherapy represents a potential therapeutic option
for patients with HCC [23].
Many reports suggested that the antitumor activity by
several traditional Chinese herbs as mediated via augmenta-
tion of the immune response [24–26]. Therefore, we inves-
tigated the effect of traditional medicine, SB on immunity.
Hepatoma H22-bearing mice were used to elucidate the
immunomodulatory function of anti-tumor activity.
The human HCC cell line, HepG2 cells has been ex-
tensively used for vitro experiment [27, 28]. Based on
the previous studies [29–31], we selected different con-
centrations of SBE in our study, and examined their ef-
fects on HepG2 cell in vitro and the tumor growth in
hepatoma H22-bearing mice. The results of this study
showed that SBE could not only inhibit the proliferation
of HepG2 in vitro, but also inhibit the tumor growth in
hepatoma H22-bearing mice. It demonstrates that SBE
has the inhibitory effects on the tumor growth.
In this study, we investigated the underlying immuno-
modulatory function of SBE on the tumor growth of
hepatoma H22-bearing mice. Natural killer cells (NK
cell) belong to the innate immune system and play a
critical role in the host defense against cancer [32]. NK
cells represent one major component of the liver micro-
environment. In addition to direct killing of tumor cells,
NK cells are able to rapidly release immunomodulatory
cytokines, which activate leukocytes of both the innate
and adaptive immune system. Unlike CTLs, however,
the killing by NK cells is non-specific and NK cells do
not need to recognize antigen/MHC on the target cell.
NK cells can react against and destroy target cell without
prior sensitization to it. The results of our study showed
SBE treatment significantly enhanced the killing activity
of NK cells from splenocytes in H22 tumor-bearing
Fig. 5 Cytotoxicity of NK cells is enhanced by SBE. a NK cells from control and SBE treated groups were incubated with indicated effector-to-
target cell (E/T) ratios (5:1, 10:1). CFSE-positive cells were gated, and the percentage of PI-positive cells within this gate is shown. b Cytotoxicity of
NK cells between the two groups with indicated effector-to-target cell (E/T) ratios (5:1, 10:1) is shown. This experiment was performed three times
independently, yielding comparable results. *P < 0.05 versus control
Fig. 4 The effect of SBE treatment on the growth of H22 tumors. The
volume of tumors of SBE group (50 mg/kg/day) was significantly
smaller compared with the control group. Data are representative of
three independent experiments. *P < 0.05 versus control
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mice. It suggested that SBE treatment could enhance
NK cells’ killing tumor ability.
Regulatory T cells characterized by the expression of the
transcription factor Foxp3 play a pivotal role in immune
homeostasis and suppress function of effector cells such as
CD4+ T cells, CD8+ T cells, and natural killer (NK) T cells
[33]. Previous study [34] has demonstrated that an
abundant accumulation of Treg cells was found in tumor
regions compared with nontumor regions in HCC
patients. Our study also found that the amount of
CD4+CD25+Foxp3+ regulatory T cells in tumor tissue was
significantly decreased in SBE treated group. This result
confirmed the view that tumor cells can recruit these Treg
cells to inhibit the efficiency of cancer immunotherapy.
The production of IL-17 characterizes a subset of CD4+
helper T cells (Th17 cells). T helper 17 (Th17) cells are an
important inflammatory component and have been shown
to promote inflammation in a number of autoimmune
diseases [35]. The development of Th17 cells is distinct
from the development of Th1, Th2 and regulatory T cells
and is characterized by unique transcription factors and
cytokine requirements. A previous study [20] reported
that Th17 cells were significantly increased in tumors of
HCC compared with corresponding non-tumor regions,
accumulation of intratumoral IL-17-producing cells may
promote tumor progression through fostering angiogen-
esis, and intratumoral IL-17-producing cell could serve as
a potential prognostic marker and a novel therapeutic tar-
get for HCC. The results of our study showed that SBE
treatment significantly decreased the amount of CD4+IL-
17+ (Th17) cells in the tumor tissue. This may partially
cause the inhibition of tumor growth.
NK cell, Treg and Th17 cells exert their function
through cytokine secreted in the tumor microenviron-
ment. Therefore, we detected the Th1, Treg and Th17
related cytokine in the serum of H22 tumor-bearing
Fig. 7 SBE treatment down-regulated the amount of CD4+IL-17+Th17 cells. a Tumor-infiltrating lymphocytes (TILs) were isolated and stimulated,
and the cells were stained with anti-CD4-FITC followed by labeling with anti-IL-17-PE cytokine Abs. b The amount of Th17 cells in tumor micro-
environment between the two groups is shown. Data are representative of three independent experiments. *P < 0.05 versus control
Fig. 6 SBE treatment down-regulated the population of Treg cells. Tumors from control and SBE treated groups were digested with collagenase and
hyaluronidase. a Tumor-infiltrating lymphocytes (TILs) were isolated, stained with anti-Foxp3-APC after surface staining with anti-CD25-PE and anti-
CD4-FITC. b The amount of Treg cells in tumor microenvironment between the two groups is shown. Data are representative of three independent
experiments. *P < 0.05 versus control
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Fig. 9 3D ultrasound pictures for tumor growth in SBE, saline solution, and SBE combined with IL-17A treatment mice. Fifteen days after implantation
of tumor cells, the tumors of SBE, control, and IL-17A combined with SBE treatment mice were observed under 3D ultrasound, and their volume was
calculated by 3D ultrasound
Fig. 8 SBE treatment up-regulated Th1 cytokine and down-regulated Th17 and Treg related cytokine. The concentrations of TGF-β, IL-10, IL-17A,
IL-2 and IFN-γ in the serum of mice were measured by ELISA. The amount of TGF-β (a), IL-10 (b), IL-17A (c), IL-2 (d) and IFN-γ (e) between the
two groups is shown respectively. Data are representative of three independent experiments. **P < 0.01 versus control
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mice. The results of our study showed SBE treatment
up-regulated Th1 cytokine (IL-2 and IL-12p70) and
down-regulated Th17 (IL-17) and Treg (TGF-β and IL-
10) related cytokine in the serum of tumor bearing mice.
The main producing cytokine of Th17, recombinant IL-
17A administration could reverse the anti-tumor effects
of SBE. It suggested that Th17 could partially cause the
tumor growth, and SBE might inhibit the tumor growth
through the intervention of Th17 cell.
The present study has limitations. First, we tested only
three dosages of SBE in inhibiting the growth of hepa-
toma H22 cells in vivo. More experiments are needed to
explore other dosages of SBE, and there might be a more
appropriate dosage of SBE which is also effective in inhi-
biting the growth of hepatoma H22 cells in vivo. Second,
SBE using in our study included many components. More
experiments are needed to explore which component is
the most important for inhibition of tumor growth.
Conclusion
In summary, SBE could inhibit the proliferation of HepG2
cells in vitro. Furthermore, SBE also could inhibit the
growth of H22 implanted tumor in hepatoma H22-
bearing mice, and this function might be associated with
immunomodulatory activity through down-regulating of
Treg cells and manipulating Th1/Th17 immune response.
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